期刊文献+

预混胰岛素类似物治疗2型糖尿病剂量的系统评价 被引量:3

Dose analysis of premixed insulin analogue from one to triple daily injection in patients with type 2 diabetes: a systematic review
原文传递
导出
摘要 目的系统评价预混胰岛素类似物1~3针治疗2型糖尿病的剂量情况.方法电子检索PubMed数据库,文献检索时间为2009年1月至2014年11月,英文检索关键词包括type 2 diabetes、premixed insulin analogue、aspart30、aspart50、lispro25、lispro50、randomized controlled trial、dose等.纳入预混胰岛素类似物1~3针治疗2型糖尿病的所有随机对照试验,提取符合纳入标准的数据,由于本研究数据不能进行Meta分析,则进行描述性的定性分析.结果最终纳入11项随机对照试验,文献发表时间为2009-2013年,试验组共纳入3555例患者.各研究最终胰岛素用量不尽相同,最小用量0.25U·kg^-1·d^-1,最大用量(1.19±0.44)U·kg^-1·d^-1.最终胰岛素用量不同的原因是多方面的,其中各临床试验设计方面的差异以及患者自身的个体性差异导致的各研究间的异质性可能是导致这种差异的主要原因.结论胰岛素应用的剂量应该体现个体化原则,根据患者的种族、病程、BMI、胰岛素抵抗的程度以及是否与口服药联合治疗等情况而定,不能用一个固定的公式或者模式计算.今后仍有必要进一步开展高质量、大样本、长期随访的预混胰岛素类似物治疗2型糖尿病的随机对照试验. ObjectiveTo systemically review dose of premixed insulin analogue from one to triple daily injection in patients with type 2 diabetes.Methods Database search of PubMed (from January 2009 to November 2014) was carried out. English key words included type 2 diabetes, premixed insulin analogue, aspart 30, aspart 50, lispro 25, lispro 50, randomized controlled trial, dose. All randomized controlled trials about premixed insulin analogue from one to triple daily injection in patients with type 2 diabetes were included. To extract the eligible data and perform descriptive qualitative analysis rather than Meta-analysis to the data.Results Eventually, 11 randomized controlled trials and 3 555 patients were included, with publishing time from 2009 to 2013. The final insulin dosage of those researches quite different, ranged from 0.25 U2kg-12d-1 to (1.19±0.44)U2kg-12d-1. Several reasons contributed to the difference. The different study design and the heterogeneity among these clinical trials could be the main cause of the discrepancy.ConclusionsThe insulin dose should follow the principle of individuation. The appropriate dose should be chosen according to the patient's race, course, BMI, insulin resistance and oral agents combined with insulin. It is impossible to find a unified dose to normalize the blood glucose.
出处 《中华临床医师杂志(电子版)》 CAS 2015年第24期113-117,共5页 Chinese Journal of Clinicians(Electronic Edition)
基金 国家自然科学基金(81070637) 山东省科技发展计划(2010GSF10228 2012GGH11862胰外) 山东省自然基金(Y2006C76 Y2008C73 ZR2010HM044)
关键词 糖尿病 2型 随机对照试验 预混胰岛素类似物 剂量 系统评价 Diabetes mellitus,type 2 Randomized controlled trial Premixed insulin analogue Dose Systematic review
  • 相关文献

参考文献14

  • 1Akram K, Pedersen-Bjergaard U, Carstensen B, et al. Frequency andrisk factors of severe hypoglycaemia in insulin-treated Type 2diabetes: a cross-sectional survey[J]. Diabet Med, 2006, 23(7):750-756.
  • 2Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associatedautonomic failure in insulin-dependent diabetes mellitus. Recentantecedent hypoglycemia reduces autonomic responses to, symptomsof, and defense against subsequent hypoglycemia[J]. J Clin Invest,1993, 91(3): 819-828.
  • 3Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Associationof Clinical Endocrinologists’ comprehensive diabetes managementalgorithm 2013 consensus statement-executive summary[J]. EndocrPract, 2013, 19(3): 536-557.
  • 4Kalra S, Plata-Que T, Kumar D, et al. Initiation with once-dailyBIAsp 30 results in superior outcome compared to insulin glargine inAsians with type 2 diabetes inadequately controlled by oralanti-diabetic drugs[J]. Diabetes Research and Clinical Practice, 2010,88(3): 282-288.
  • 5Yang W, Xu X, Liu X, et al. Treat-to-target comparison between oncedaily biphasic insulin aspart 30 and insulin glargine in Chinese andJapanese insulin-na ve subjects with type 2 diabetes[J]. CurrentMedical Research & Opinion, 2013, 29(12): 1599-1608.
  • 6Lee YH, Lee BW, Chun SW, et al. Predictive characteristics ofpatients achieving glycaemic control with insulin after sulfonylureafailure[J]. Int J Clin Pract, 2011, 65(10): 1076-1084.
  • 7Ligthelm RJ. A comparison of twice-daily biphasic insulin aspart70/30 and once-daily insulin glargine in persons with type 2 diabetesmellitus inadequately controlled on basal insulin and oral theraphy: arandomized, open-label study[J]. Endocrine Prctice, 2011, 17(1):41-50.
  • 8Bowering K, Reed VA, Felicio J, et al. A study comparing insulinlispro mix 25 with glargine plus lispro therapy in patients with Type2 diabetes who have inadequate glycaemic control on oralantihyperglycaemic medication: results of the Paradigm study[J].Diabetic Medicine, 2012, 29(9): 263-272.
  • 9Liebl A, Prager R, Binz K, et al. Comparison of insulin analogueregimens in people with type 2 diabetes mellitus in the PREFERStudy: a randomized controlled trial[J]. Diabetes Obesity andMetabolism, 2009, 11(1): 45-52.
  • 10John B, Bruce HR, William H, et al. DURAbility of Basal VersusLispro Mix75/25 Insulin Efficacy (DURABLE) Trial 24-WeekResults[J]. Diabetes Care, 2009, 32(6): 1007-1113.

同被引文献23

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部